The JETi Registry is a prospective, multi-center, observational study to collect real-world data on the safety, performance, and clinical benefits of the JETi® Peripheral Thrombectomy System (JETi System) for the treatment of acute/subacute thrombosis in the peripheral vasculature.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

William Kuo, MD

Intervention(s):

device: JETi Peripheral Thrombectomy System

Eligibility

Inclusion Criteria:

• Subject is expected to be treated for acute/subacute thrombosis in the peripheral vasculature with the JETi Peripheral Thrombectomy System.
• Subject or legally authorized representative must provide written informed consent
• Subject must be ≥ 18 years of age

Exclusion Criteria:

• Subject has previously been registered in the JETi Registry in the last 12 months unless treated in the contralateral limb/different anatomy; patients treated in the contralateral limb/different anatomy within the last 12 months may re-enroll in the study.
• Subject is currently participating in another drug or device clinical investigation.
• Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly spreading novel infectious agent within the past 20 days.

Ages Eligible for Study

18 Years and older

Genders Eligible for Study

All